Expliquer à l'aide d'études animales le mode d'action des psychostimulants.
Méthode
Une revue de la littérature psychiatrique sur l'usage des psychostimulants chez l'enfant et l'adulte.
Résultats
En étudiant la littérature psychiatrique, il s'avère que 50 ans après l'introduction de l'amphétamine en clinique, les psychostimulants sont des médicaments utilisés, notamment le méthylphénidate, dans le traitement de l'hyperactivité de l'enfant avec ou sans déficit de l'attention. En revanche, chez l'adulte les psychostimulants cherchent encore leur voie, malgré des études dans le traitement de la dépression et d'autres maladies mentales. Seule la narcolepsie semble être justifiable de tels produits.
Conclusion
La preuve est largement faite de l'utilité des psychostimulants chez l'enfant. Chez l'adulte, ils pourraient être utiles à condition de mieux étudier les symptômes cibles.
References
1.
BourinM., CharpentierA.Mécanismes d'action supposés de quelques effets comportementaux de l'amphétamine.J Psy Biol Ther1986; 23: 4–8.
2.
SimonP., ChermatR., DoareL.Interactions imprévues de divers psychotropes avec les effets du barbital et du phenobarbital chez la souris.J Pharmacol1982; 13: 41–252.
3.
SimonP.Pharmacologie et mécanismes d'action des psychostimulants. In: Séminaire de Psychiatrie Biologique, Tome 3, 1983, Editions Médicales Fournier Frères.
4.
GlovinskiJ.Effects of amphetamine on various aspects of catecholamine metabolism in the central nervous system of the rat. In: Amphetamines and related compounds.CostaE, and GarattiniS, editors. New York.-Raven Press; 1970; 301–306.
5.
CookJ., SchanbergS.The effects of methamphetamine on behavior and on the uptake, release and metabolism of norepinephrine.Biochem Pharmacol1970; 19: 1165–1175.
6.
LeonardB.Effect of four amphetamines on brain biogenic amines and their metabolites.Biochem Pharmacol1972; 21: 1289–1297.
7.
RutiedgeC.The mechanisms by which amphetamine inhibits oxydative deamination of norepinephrine in brain.J Pharmacol Exp Ther1970; 171: 188–195.
8.
SnyderS.Catecholamines in the brain as mediators of amphetamine psychosis.Arch Gen Psychiat1972; 27: 169–179.
FernandoJ., CurzonG.Effect of d-amphetamine of tryptophan and other aromatic amino acids in brain.Eur J Pharmacol1978; 49: 339–349.
11.
KimI., KornhuberJ., BrandU.Effects of chronic amphetamine treatment on the glutamate concentration in C S F and brain.Neurosci Lett1981; 4: 93–96.
12.
GoldsteinA.Wakefulness caused by caffeine.Arch Pharma Exp Pathol1964; 248: 269–278.
13.
GoldsteinA., KaiserS.Psychotropic effects of caffeine in man. III. A questionnaire survey of coffee drinking and its effects on a group of housewives.Clin Pharmacol Ther1969; 10: 477–488.
14.
GoldsteinA., KaiserS., WhitbyO.Psychotropic effects of caffeine in man. IV. Quantitative and qualitative differences associated with habituation to coffee.Clin Pharmacol Ther1969; 10: 489–497.
15.
DalyJ.W., BrunsR.F., SnyderS.H.Adenosine receptors in the central actions of methylxanthines.Life Sci1981; 28: 2083–2097.
16.
BradleyC.The behavior of children receiving benzedrine.Amer J Psychiatry1927; 94: 577–58.
17.
BarkleyR.A.A review of stimulant drug research with hyperactive children.J Child Psychol Psychiat1977; 18: 137–165.
18.
DugasM., AlbertE., HalfonO.L'hyperactivité chez l'enfant. Paris, Ed Presses Universitaires de France, 1987.
19.
GittelmanR., MannuzzaS., ShenkerR.Hyperactive boys almost grown up. I. Psychiatric status.Arch Gen Psychiatry1985; 42: 937–947.
20.
ChiarelloR.J., JonathanO., ColeJ.The use of psychostimulants in general psychiatry. A reconsideration.Arch Gen Psychiatry1987; 44: 286–295.
KavaleK.The efficacy of stimulant drug treatment of hyperactivity (A meta analysis).J Learning1982; 15: 280–289.
23.
TaylorE., CharcharR., ThorlyG.Which boys respond to stimulant medication? a controlled trial of methylphenidate in boys with disruptive behaviour.Psychol Med1986; 17: 121–143.
24.
RapoportJ.L., BuchsbaumM., ZahnT.Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys.Science1978; 199: 560–562.
25.
WerryJ.S.Pediatric psychopharmacology: the use of behavior modifying drugs in children.New York: Brunner/Mazel;1978.
26.
WeissB., LatiesV.G.Enhancement of human performance by caffeine and the amphetamines.Pharmacol Rev1962; 14: 1–36.
27.
HechtmanL., WeissG., PerlmanT.Young adult outcome of hyperactive children who received long-term stimulant treatment.J Am Acad Child Psychiatry1984; 23: 261–269.
28.
WeissG., KrugerE., DanielsonU.Effect of long-term treatment of hyperactive children with methylphenidate.Can Med Assoc J1975; 112: 159–165.
29.
Gittelman KleinR.Pharmacotherapy of childhood hyperactivity: an update. Psychopharmacology: The Generation of progress.MeltzerH.Y., ed. New York: Raven Press,1987.
30.
CantwellD.P., CarlsonG.A.Stimulants. In: WerryJ.S., ed. Pediatric psychopharmacology: the use of behavior modifying drugs in children.New York: Brunner/Mazel.1978; 171–207.
31.
FriedJ., GreenhillL., TorresD.Sustained-release methylphenidate: long-term clinical efficacy in ADHD males. Presented at the American Academy of Child and Adolescent Psychiatry. Washington, DC, October 1987; 21–25.
32.
BrownR.T., SleatorE.K.Methylphenidate in hyperkinetic children: differences in dose effects on impulsive behavior.Pediatrics1979; 64: 408–411.
33.
SpragueR.L., and SleatorE.K.Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior.Science1977; 198: 1274–1276.
34.
BallingerC.T., VarleyC.K., and NolenP.A.Effects of methylphenidate on reading in children with attention defficit disorder.Am J Psychiatry1984; 141: 1590–1593.
35.
CohenN.J., SullivanJ., MindeK.Evaluation of the relative effectiveness of methylphenidate and cognitive behavior modification in the treatment of kindergarten-aged hyperactive children.J Abnorm Child Psychol1981; 9: 43–54.
36.
ConnersC.K., and SolantoM.V. In: Attention deficit disorder: diagnostic, cognitive and therapeutic understanding, BloomingdaleL.N., ed. New York:1984; 191–204.
37.
GanJ., and CantwellD.P.Dosage effects of methylphenidate on paires associate learning: positive/negative placebo responders.J Am Acad Child Psychiatry1982; 21: 237–242.
38.
PehlmanW.E., BenderM.E., CaddellJ.Methyl-phenidate and children with attention deficit disorder. Dose effects on classroom academic and social behavior.Arch Gen Psychiatry1985; 42: 948–952.
39.
RapportM.D., StonerG., DuPaulJ.Methyl-phenidate in hyperactive children: differential effects of dose on academic, learning, and social behavior.J Abnorm Child Psychol1985; 13: 227–243.
40.
RapportM.D., DuPaulG.J., StonerG.Comparing classroom and clinic measures of attention deficit disorder: differential idiosyncratic and dose response effects of methylphenidate.J Consult Clin Psychol1986; 54: 334–341.
41.
SolantoM.V., and ConnersC.K.A dose-response and time-action analysis of autonomic and behavioral effects of methylphenidate in attention deficit disorder with hyperactivity.Psychophysiology1982; 19: 658–667.
42.
WalkerM.A.In: Drugs and mental retardation.BreuningS.E., PolingA.D., ThomasC.C., editors. Springfield IL: 1982; 235–266.
43.
PeekeS., HallidayR., CallawayE.Effects of two doses of methylphenidate on verbal information processing in hyperactive children.J Clin Psychopharmacol1984; 4: 82–88.
44.
GualtieriC.T., WarginW., KanoyR.Clinical studies of methylphenidate serum levels in children and adults.J Am Acad Child Psychiatry1982; 21: 19–26.
45.
DugasM., AlbertE., MourenM.C.A propos d'un cas d'hallucinations sous methylphénidate chez un garçon hyperkinetique de 8 ans.J Toxicol Clin1985; 5: 195–199.
SatterfieldJ.H., CantwellD.P., SchellA.et al. Growth of hyperactive children treated with methylphenidate.Arch Gen Psychiatry1982; 39: 486–487.
48.
MattesJ., GittelmanR.Growth of hyperactive children on maintenance methylphenidate.Arch Gen Psychiatry1983; 40: 317–321.
49.
VincentJ., VarleyC.K., LegerP.Effects of methylphenidate on early adolescent growth.Am J Psychiatry1990; 147: 501–502.
50.
BeckL., LangfordW., MacKayM.Childhood chemotherapy and later drug abuse and growth curve: a follow up study of 30 adolescents.Am J Psychiatry1975; 132: 436–438.
51.
WeissG.The natural history of hyperactivity in childhood and treatment with stimulant medication at different age: a summary of research findings.Int J Ment Health1975; 4: 213–216.
52.
CasatC.D., PleasantsD.Z., Van Wyck FleetJ.A double-blind trial of bupropion in children with attention deficit disorder.Psychopharmacol Bull1987; 23: 120–122.
53.
ZametkinA., RapoportJ.L., MurphyD.L.Treatment of hyperactive children with monoamine oxidase inhibitors. U: plasma and urinary monoamine findings after treatment.Arch Gen Psychiatry1985; 42: 969–973.
54.
HuntR.D., MinderaaR.B., CohenD.J.Clonidine benefits children with attention disorder and hyperactivity: report of a double-blind placebo cross-over therapeutic trial.J Am Acad Child Psychiatry1985; 24: 617–629.
55.
ConnersC.K.In: Recent advances in child psychopharmacology.Gittelman-KleinR., editor. New York: Human Sciences Press;1975: 136–147.
56.
FirestoneP., DaveyJ., GoodmanJ.T.The effects of caffeine and methylphenidate on hyperactive children.J Am Acad Child Psychiatry1978; 17: 445–456.
57.
GarfmkelB., WebsterC., and SlomanL.Methylphenidate and caffeine in the treatment of children with minimal brain dysfunction?Am J Psychiatry1975; 132: 723–728.
58.
GrossM.Caffeine in the treatment of children with minimal brain dysfunction or hyperkinetic syndrome.Psychomatics1975; 16: 26–27.
59.
HarveyD.H., and MarshR.W.The effects of decaffeinated coffee versus whole coffee on hyperactive children.Dev Med Child Neurol1978; 20: 81–86.
60.
GittelmanR., AbikoffH., PollackE. In: Hyperactive children: the social ecology of identification and treatment.WhalenC.K., HenkerB., editors. New York: Academic Press;1980; 221–243.
61.
O'LearyS.G. and PelhamW.E.Behavior therapy and withdrawal of stimulant medication in hyperactive children.Pediatrics1978; 61: 211–217.
62.
WorlraichM., DrummondT., SalomonM.K.Effects of methylphenidate alone and in combination with behavior modification procedures on the behavior and academic performance of hyperactive children.J Abnorm Child Psychol1978; 6: 149–161.
63.
FirestoneP., KellyM.J., GoodmanJ.T.Differential effects of parents training and stimulant medication with hyperactives: a progress report.J Am Acad Child Psychiatry1981; 20: 135–147.
64.
AbikoffH., GittelmanR.Hyperactive children treated with stimulants.Is cognitive training a useful adjunct? Arch Gen Psychiatry1985; 42: 953–961.
65.
BrownR.T., WynneM.E., MedenisR.Methylphenidate and cognitive therapy: a comparison of treatment approaches with hyperactive boys.J Abnorm Child Psychol1985; 13: 69–87.
66.
AmeyB., MinichielloM.D., BrownG.L.Agression in hyperactive boys: response to d-amphetamine.J Am Acad Clin Psychiatry1984; 23: 291–294.
67.
TaylorE., ScharcharR., WieselbergM.Changes in family function and relationship in children who respond to methylphenidate.J Child Psychiatry1987; 26: 728–732.
68.
RudelR.G., HelfgottE.Effect of piracetam on verbal memory-4 of dyslexic boys.J Am Acad Child Psychiatry1984; 23: 695–699.
69.
WilsherL.R.A brief review of studies of piracetam in dyslexia.J Psychopharmacol1987; 1: 95–100.
70.
BlumR.H.Mind altering drugs and dangerous behaviour. In: President's commission on law enforcement and administration of justice task report.Washington DC: US Government Printing office;1967.
FawcettJ., SiompoulosV.Dextroamphetamine response as a possible predictor of improvement with tricyclic therapy in depression.Arch Gen Psychiatry1971; 25: 247–255.
73.
Van KammenD., MurphyD.L.Predication of Imipramine antidepressant response by one day d-amphetamine trial.Am J Psychiatry1978; 135: 1179–1184.
74.
BrownP., BrawleyP.Dexamethasone suppression test and mood response to methylphenidate in primary depression.Am J Psychiatry1983; 140: 990–993.
75.
EttigiP.G., HayesP.E., NarasirnhachariN.D-amphetamine response and dexamethasone suppression test as predictors of treatment outcome in unipolar depression.Biol Psychiatry1983; 18: 499–504.
76.
JoyceP.P.Mood response to methylphenidate and the dexamethasone suppression test as predictors of treatment response to zimelidine and lithium in major depression.Biol Psychiatry1985; 20: 598–604.
77.
QuitkinF.M., LeibowitzM.R., StewartJ.W.Deprenyl in typical depressives.Arch Gen Psychiatry1984; 41: 777–781.
78.
GoffD.The stimulant challenge test in depression.J Clin Psychiatry1986; 47: 538–543.
79.
GoffD.Stimulants in depression.Biol Ther Psychiatry1987; 10: 9.
80.
MattesJ.A.Methylphenidate in mild depression: a double bind controlled trial.J Clin Psychiatry1985; 46: 525–527.
81.
LandmanE., PreisigR., PerlmanM.A pratical mood stimulant.J Med Soc New Jersey1958; 55: 55–58.
82.
WarnekeL.Psychostimulants in psychiatry.Can J Psychiatry1990; 35: 3–10.
83.
KaufmannM., MurrayG., CassemN.Use of psychostimulants in medically ill depressed patients.Psychosomatics1982; 23: 817–819.
84.
KatonW., RaskindM.Treatment of depression in the mentally ill elderly with methylphenidate.Am J Psychiatry1980; 137: 963–965.
85.
AskinasiC., WeintraubR., KaramouzM.Elderly depressed females as a possible subgroup of patients responsive to methylphenidate.J Clin Psychiatry1986; 47: 467–469.
86.
LapierreY.D., and HrdinaP.D.Nooanaleptiques In: Pharmacologie clinique, bases de la thérapeutique.Expansion Scientifique Française1988; 271–1281.
87.
NathansonM.H.The central action of betaminoprophyl-benzine (benzedrine).J Am Med Assoc1937; 108: 528–531.
88.
WilburD.L., MacLeanA.R., AllenE.Clinical observation on the effect of benzedrine sulphate.J Am Med Assoc1937; 109-. 549–554.
89.
MeadleyR.G.A new antifatigue agent in general practice.Practitioner1965; 195: 680–683.
90.
SalitI.Chronic EBV infections (post infectious neuromyasthenia).Med North Amer1987; 10: 1944–1950.
91.
WhartonR., PerelJ., DaytonP.A potential clinical use for methylphenidate with tricyclic antidepressants.Am J Psychiatry1971; 127: 1619–1625.
92.
PerelJ., BlackN.In vitro metabolism studies with methyphenidate.Fed Proc1970; 29: 345.
93.
DaytonP., PerelJ.Inhibition of drug metabolism by methylphenidate. In: Abstracts on the fourth international congress in pharmacology.Basil: Schwab & Co; 1969.
94.
LalH., PuriS.K., FullerG.C.Inhibition of hepatic hexobarbital metabolism by dextroamphetamine.Psychopharmacologia1970; 16: 395–398.
95.
DrimmerE., GitlinM.D., GwertsmanM.D.Desipramine and methyl-phenidate combination treatment for depression: case report.Am J Psychiatry1983; 140: 241–243.
96.
FeighnerJ., HerbsteinJ., DamloujiN.Combined MAOI. TCA and direct stimulant therapy of treatment-resistant depression.J Clin Psychiatry1985; 46: 206–209.
97.
BeckmannV.H., HeinemanH.D-amphetamin beim manischen syndrom.Arzneim Forsch1976; 26: 1185–1186.
98.
JanowskyD.S., El-YoussefK., DavisJ.M.Provocation of schizophrenic symptoms by intravenous administration of methylphenidate.Arch Gen Psychiatry1973; 28: 185–191.
99.
BrownW.A., MullerB.Alleviation of manic symptoms with catecholamine agonists.Am J Psychiatry1979; 136: 230–231.
100.
InselT.R., HamiltonJ.A., GuttmacherL.B.D-amphetamin in obsessive compulsive disorder.Psychopharmacology1980; 80: 231–235.
101.
JoffeR.T., SwinsonR.P.Methylphenidate in primary obsessive-compulsive disorder.J Clin Psychopharmacol1987; 7: 420–422.
WenderP.H., ReimheirF.W., WoodD.R.Attention deficit disorder in adults.Arch Gen Psychiatry1981; 38: 449–456.
104.
WenderP.H., ReimheirF.W., WoodD.A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type in adults.Am J Psychiatry1985; 142: 547–552.
105.
MattesJ., BoswellL., OliverH.Methylphenidate effects on symptoms of attention deficit disorder in adults.Arch Gen Psychiatry1984; 41: 1059–1053.
106.
WoodD.R., ReimheirF.W., WenderP.H.Diagnosis and treatment of minimal brain dysfunction in adults.Arch Gen Psychiatry1976; 33: 1453–1460.
107.
LapierreY.Les Psychostraralaras. In: Les médicaments en neurologie et psychiatrie.BourinM., editor. Paris: Masson;1990; 84–89.
108.
BourinM., Couëtoux du TertreA.Les médicaments de l'éveil chez le sujet âgé.Psychol Med1992; 24: 833–835.
